These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26297253)

  • 1. Down-regulation of cytoplasmic PLZF correlates with high tumor grade and tumor aggression in non-small cell lung carcinoma.
    Xiao GQ; Li F; Findeis-Hosey J; Hyrien O; Unger PD; Xiao L; Dunne R; Kim ES; Yang Q; McMahon L; Burstein DE
    Hum Pathol; 2015 Nov; 46(11):1607-15. PubMed ID: 26297253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.
    Xiao GQ; Unger P; Yang Q; Kinoshita Y; Singh K; McMahon L; Nastiuk K; Sha K; Krolewski J; Burstein D
    PLoS One; 2015; 10(3):e0121318. PubMed ID: 25807461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers.
    Wang X; Wang L; Guo S; Bao Y; Ma Y; Yan F; Xu K; Xu Z; Jin L; Lu D; Xu J; Wang JC
    FASEB J; 2013 Oct; 27(10):4194-203. PubMed ID: 23804241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
    Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G
    World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
    Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
    Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-downregulation of PTEN, KAI-1, and nm23-H1 tumor/metastasis suppressor proteins in non-small cell lung cancer.
    Goncharuk VN; del-Rosario A; Kren L; Anwar S; Sheehan CE; Carlson JA; Ross JS
    Ann Diagn Pathol; 2004 Feb; 8(1):6-16. PubMed ID: 15129904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.
    Warnecke-Eberz U; Bollschweiler E; Drebber U; Pohl A; Baldus SE; Hoelscher AH; Metzger R
    Oncol Rep; 2008 Sep; 20(3):619-24. PubMed ID: 18695914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between expression of caveolin-1 and pERK1/2 and prognosis in non-small cell lung cancer].
    Liu HX; Xing LX; Wang HB; Yang JQ; Sun YM
    Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):615-9. PubMed ID: 19094586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
    Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
    Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WWOX expression in different histologic types and subtypes of non-small cell lung cancer.
    Donati V; Fontanini G; Dell'Omodarme M; Prati MC; Nuti S; Lucchi M; Mussi A; Fabbri M; Basolo F; Croce CM; Aqeilan RI
    Clin Cancer Res; 2007 Feb; 13(3):884-91. PubMed ID: 17289881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association of HAb18G with clinicopathologic features and prognosis in non-small cell carcinoma of lung].
    Xu XY; Zhi C; Li YM; Qi WJ; Mei JJ; Yan ZM; Shen H
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):151-5. PubMed ID: 22800476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Over-expression of osteopontin in non-small cell lung cancers: its clinical significance].
    Hu Z; Xiao T; Lin DM; Guo SP; Zhang ZQ; Di XB; Cheng SJ; Gao YN
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):591-5. PubMed ID: 18210878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of pRb2/p130 expression is associated with unfavorable clinical outcome in lung cancer.
    Caputi M; Groeger AM; Esposito V; De Luca A; Masciullo V; Mancini A; Baldi F; Wolner E; Giordano A
    Clin Cancer Res; 2002 Dec; 8(12):3850-6. PubMed ID: 12473599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer.
    Bai XY; Lin JY; Zhang XC; Xie Z; Yan HH; Chen ZH; Xu CR; An SJ; Sheng GM; Wu YL
    Cancer Biomark; 2013; 13(1):37-47. PubMed ID: 23736020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of CD88 predicts poor prognosis in non-small-cell lung cancer.
    Gu J; Ding JY; Lu CL; Lin ZW; Chu YW; Zhao GY; Guo J; Ge D
    Lung Cancer; 2013 Aug; 81(2):259-65. PubMed ID: 23706417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between RGS5 expression and cancer differentiation and metastasis in non-small cell lung cancer.
    Huang G; Song H; Wang R; Han X; Chen L
    J Surg Oncol; 2012 Mar; 105(4):420-4. PubMed ID: 21780128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.